Stock Price, News, Quote and Profile of LANTHEUS HOLDINGS INC(NASDAQ:LNTH) stock

LANTHEUS HOLDINGS INC

NASDAQ:LNTH (12/23/2024, 4:15:57 PM)

After market: 91.01 0 (0%)

91.01

+1.72 (+1.93%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryHealth Care Equipment & Supplies

GICS SubIndustryHealth Care Supplies

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%15.65%

Sales Q2Q%18.37%

CRS80.16

6 Month12.88%

Overview

Earnings (Last)11-06 2024-11-06/bmo

Earnings (Next)02-20 2025-02-20/amc

Ins Owners1.46%

Inst Owners101.09%

Market Cap6.33B

Shares69.53M

PE13.11

Fwd PE12.98

Dividend YieldN/A

Analysts82.22

Short Float %6.91%

Short Ratio4.34

IPO06-25 2015-06-25

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The company is headquartered in North Billerica, Massachusetts and currently employs 834 full-time employees. The company went IPO on 2015-06-25. The firm classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its pipeline also includes breast and other cancers. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, Ga-DOTA-RM2, and others. Its pipeline includes B amyloid positron emission tomography (PET) imaging agent, NAV-4694, also known as F18-flutafuranol.